Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
CymaBay Therapeutics, Inc. CBAY
$10.04
-$0.24 (-2.43%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
1005040822.00000000
-
week52high
11.22
-
week52low
1.68
-
Revenue
0
-
P/E TTM
-7
-
Beta
0.26159100
-
EPS
-1.14000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| B. Riley Securities | Buy | Buy | 18 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 16 мая 2022 г. |
| Raymond James | Strong Buy | Strong Buy | 11 ноя 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 03 авг 2021 г. |
| JonesTrading | Buy | 14 июн 2021 г. | |
| Raymond James | Strong Buy | Strong Buy | 17 янв 2023 г. |
| Cantor Fitzgerald | Overweight | Overweight | 31 янв 2023 г. |
| Piper Sandler | Overweight | Overweight | 30 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | A | 2142857 | 2142857 | 26 янв 2023 г. |
| Wills Robert James | A | 25000 | 25000 | 25 янв 2023 г. |
| Loewy Caroline M | A | 25000 | 25000 | 25 янв 2023 г. |
| WIGGANS THOMAS G | A | 25000 | 25000 | 25 янв 2023 г. |
| EMSTER KURT VON | A | 25000 | 25000 | 25 янв 2023 г. |
| Dorling Janet | A | 25000 | 25000 | 25 янв 2023 г. |
| Lefebvre Eric | A | 25000 | 25000 | 25 янв 2023 г. |
| KIM DENNIS D | A | 180000 | 180000 | 25 янв 2023 г. |
| Quinlan Paul T | A | 215000 | 215000 | 25 янв 2023 г. |
| Menold Daniel | A | 100000 | 100000 | 25 янв 2023 г. |
Новостная лента
CymaBay Therapeutics to Report First Quarter of 2023 Financial Results on Monday, May 15, 2023
GlobeNewsWire
10 мая 2023 г. в 08:00
NEWARK, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Monday, May 15, 2023 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2023 and to provide a business update.
CymaBay Therapeutics: Slow But Steady Progress
Seeking Alpha
09 мая 2023 г. в 14:45
Today, we shine the spotlight on CymaBay Therapeutics, Inc., whose stock has had a big rally in 2023. The company is advancing its lead asset Seladelpar towards approval and recently signed a licensing deal in Japan, but cash burn remains a concern.
Four Potential Breakout Stocks For The Rest Of The Week - Asure Software (NASDAQ:ASUR), CymaBay Therapeutics (NASDAQ:CBAY)
Benzinga
19 апр 2023 г. в 08:58
In trading, there will always be elegance in simplicity. If your trading operation lacks a cadre of PhDs to crunch data like Renaissance Technologies or D.E.
CymaBay Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
GlobeNewsWire
17 апр 2023 г. в 08:00
NEWARK, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ.
Here's Why Momentum in CymaBay Therapeutics Inc. (CBAY) Should Keep going
Zacks Investment Research
29 мар 2023 г. в 09:59
CymaBay Therapeutics Inc. (CBAY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.